Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0127 | Zalcitabine

Molecular Formula C9H13N3O3
Molecular Weight 211.22
Structure
State solid
Clearance * 285 mL/min [HIV-infected patients receiving 1.5 mg IV infusion for 1 hour]
Volume of distribution * 0.304 to 0.734 L/kg
Route of elimination Renal excretion of unchanged drug appears to be the primary route of elimination, accounting for approximately 80% of an intravenous dose and 60% of an orally administered dose within 24 hours after dosing (n=19). Renal clearance exceeds glomerular filtration rate suggesting renal tubular secretion contributes to the elimination of zalcitabine by the kidneys.
Protein binding Less than 4%
Half life 2 hours
Absorption Bioavailability is over 80% following oral administration.
Trade names Hivid
Description nucleoside analogs ; nucleoside reverse transcriptase inhibitor (NRTI); dideoxynucleoside compound; potent inhibitor of HIV replication

J

J05AF03 Zalcitabine


[J05AF] Nucleoside and nucleotide reverse transcriptase inhibitors


[J05A] DIRECT ACTING ANTIVIRALS


[J05] ANTIVIRALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN Interfere 307
ULTRASTRUCTURE abnormalize 307
ROS PRODUCTION Increase 307
MITOCHONDRIAL DNA METABOLIC PROCESS 194
MITOCHONDRIAL DNA METABOLIC PROCESS increase 307
MITOCHONDRIAL PROTEIN TRANSLATION decrease 307

Target Dose Time Species Model Method Action Positive criterion Reference
Cytochrome c oxidase Inhibition 307
Citrate synthase, mitochondrial Inhibition 307
DNA polymerase gamma 194
Reactive oxygen species increase 307

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 46 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H351 (97.83%): Suspected of causing cancer [Warning Carcinogenicity]


H361 (15.22%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P281, P308+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H341: Suspected of causing genetic defects [Warning Germ cell mutagenicity]


H351: Suspected of causing cancer [Warning Carcinogenicity]


H361: Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


H362: May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]


H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


 P201, P202, P260, P263, P264, P270, P281, P308+P313, P314, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Acquired immunodeficiency syndrome

  • Autoimmune disorder

  • Disease progression

  • Drug intolerance

    • .beta.-D-2',3'-Dideoxycytidine .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor .beta.-D-DDC
    1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine 2', 3'-dideoxycytidine 2',3'-DIDEOXYCYTIDINE
    2',3'-Dideoxycytidine & Interferon.alpha. 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate) 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
    2',3'-Dideoxycytidine, 98% 2',3'-Dideoxycytidine, >=98% (HPLC) 2',3'-Dideoxycytidine, >=99.0% (HPLC)
    2,3-dideoxycytidine 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine 3-[(5S,2R)-5-(hydroxymethyl)oxolan-2-yl]-6-amino-3-hydropyrimidin-2-one
    4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one
    4-Amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
    42060-EP2295503A1 42060-EP2298761A1 42060-EP2305695A2
    42060-EP2305696A2 42060-EP2305697A2 42060-EP2305698A2
    42060-EP2311808A1 42060-EP2311829A1 481D892
    5-25-14-00313 (Beilstein Handbook Reference) 6L3XT8CB3I 7481-89-2
    78798-EP2298783A1 78798-EP2305695A2 78798-EP2305696A2
    78798-EP2305697A2 78798-EP2305698A2 AB0014137
    AB01085 AB2000246 AC-824
    AKOS015854844 AKOS015894505 ANW-36530
    AOB5609 BCP13878 BDBM50145605
    BPBio1_001378 BRN 0654956 BSPBio_001253
    C07207 C9H13N3O3 CAS-7481-89-2
    CCG-101050 CCRIS 692 CHEBI:10101
    CHEMBL853 CPD000058253 CS-1110
    Cytidine, 2',3'-dideoxy- Cytidine, 2',3'-dideoxy- & Colony-stimulating factor Cytidine, 2',3'-dideoxy- & Interferon.alpha.
    D 5782 D00412 D3581
    DB-019728 DB00943 DS-4152 & ddC
    DSSTox_CID_3747 DSSTox_GSID_23747 DSSTox_RID_77182
    DTXSID0023747 Dideoxycytidine EU-0100360
    GTPL4828 HIVID HMS1548B19
    HMS1571O15 HMS2051H18 HMS2090C12
    HMS2098O15 HMS2236N08 HMS3261G21
    HMS3715O15 HSDB 7156 HY-17392
    Hivid (TN) Hivid(TM) Hivid;Dideoxycytidine;NSC 606170
    Interferon AD + ddC J-700276 K278
    KS-00000MRJ KS-1130 LP00360
    LS-1645 Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine Lopac0_000360
    M-2084 MCULE-6071296177 MFCD00012188
    MLS000069636 MLS000759540 MLS001055363
    MLS001424210 MLS006011951 NC00300
    NCGC00090705-01 NCGC00090705-02 NCGC00090705-03
    NCGC00090705-05 NCGC00090705-06 NCGC00090705-07
    NCGC00090705-08 NCGC00090705-09 NCGC00090705-10
    NCGC00090705-11 NCGC00090705-13 NCGC00090705-15
    NCGC00179242-01 NCGC00257202-01 NCGC00259204-01
    NCGC00261045-01 NSC 606170 NSC-606170
    NSC-759655 NSC606170 NSC759655
    PC-SOD & ddC Pharmakon1600-01502360 Prestwick0_001037
    Prestwick1_001037 Prestwick2_001037 Prestwick3_001037
    Q-201941 Q2344582 RTC-064018
    Ro 24-2027/000 Ro-24-2027/000 Ro-24-2027000
    Ro-242027000 Ro-242027000/Ro-24-2027-000 SAM001246779
    SBB066036 SC-09165 SCHEMBL3598
    SMR000058253 SPBio_003104 SR-01000075822
    SR-01000075822-1 SR-01000736919 SR-01000736919-5
    SRI-7707 SRI-7707-13 SRI-7707-14
    SRI-7707_15 SRI-7707_17 ST069364
    ST24043185 SW197364-4 Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
    TC-064018 TimTec1_004969 Tox21_113491
    Tox21_113491_1 Tox21_201655 Tox21_303169
    Tox21_500360 UNII-6L3XT8CB3I UPCMLD-DP115
    UPCMLD-DP115:001 WREGKURFCTUGRC-POYBYMJQSA-N Z1550648753
    ZINC39906 Zalcitabine (JAN/USP/INN) Zalcitabine [USAN:INN:BAN]
    Zalcitabine [USAN:USP:INN:BAN] Zalcitabine, 2'3'-Dideoxycytidine Zalcitabine, United States Pharmacopeia (USP) Reference Standard
    Zalcitibine bmse000712 ddC
    ddC & GM-CSF ddC & IFN.alpha. ddC & Interferon.alpha.
    ddC & NP (from PHCA or HSA) ddC & sCD4 ddC (Antiviral)
    ddC;Dideoxycytidine;2',3'-Dideoxycytidine ddCyd ddC|||2',3'-Dideoxycytidine
    dideoxycytidine (DDC) s1719 zalcitabine

    DrugBank Name Zalcitabine
    DrugBank DB00943
    CAS Number 107-95-9, 7481-89-2
    PubChem Compound 24066
    KEGG Compound ID C07207
    KEGG Drug D00412
    PubChem.Substance 46507879
    ChEBI 10101
    PharmGKB PA451950
    ChemSpider 22498
    BindingDB 50145605.0
    TTD DNC000527
    Wikipedia Zalcitabine
    DPD 884

    1. Dykens et al. (2007)
    2. Chan et al. (2005)
    3. Wan et al., 2014